Advanced solid tumor Trials in Clayton, Australia
Conditions / Advanced solid tumor / Clayton, Australia
Advanced solid tumor has been the subject of sustained clinical investigation across multiple research sites.
18 total trials for this combination
Showing top 10 of 18 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06257264 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | RECRUITING | ā |
| NCT06974110 | Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | RECRUITING | ā |
| NCT06625593 | A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | RECRUITING | ā |
| NCT04801095 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | UNKNOWN | PHASE1 |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | RECRUITING | PHASE1/PHASE2 |
| NCT06172478 | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | RECRUITING | PHASE2 |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | TERMINATED | PHASE1 |
| NCT04282018 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | COMPLETED | PHASE1/PHASE2 |
| NCT06589596 | An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | RECRUITING | PHASE1 |
| NCT05267626 | Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2RĪ± Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | RECRUITING | PHASE1/PHASE2 |